Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedDec 30, 2025
DataAggregated Company Financials
Companies5
  • 7D0.5%
  • 3M4.7%
  • 1Y12.5%
  • YTD9.7%

Over the last 7 days, the Biotech industry has risen 2.6%, driven by gains from Genmab of 3.2%. In the last 12 months, the industry was up 12%. As for the next few years, earnings are forecast to decline by 12% per annum.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 30 Dec 2025DKK 177.6bDKK 40.5bDKK 19.0b6.1x9.4x4.4x
Thu, 27 Nov 2025DKK 179.4bDKK 40.9bDKK 19.1b6x9.4x4.4x
Sat, 25 Oct 2025DKK 169.9bDKK 39.0bDKK 16.8b13.3x10.1x4.4x
Mon, 22 Sep 2025DKK 162.9bDKK 38.8bDKK 16.7b12.7x9.7x4.2x
Wed, 20 Aug 2025DKK 140.3bDKK 38.8bDKK 16.7b10.6x8.4x3.6x
Fri, 18 Jul 2025DKK 127.7bDKK 27.1bDKK 7.4b11.3x17.3x4.7x
Sun, 15 Jun 2025DKK 138.2bDKK 27.2bDKK 7.4b11.6x18.7x5.1x
Tue, 13 May 2025DKK 125.9bDKK 28.0bDKK 7.9b10.1x15.9x4.5x
Thu, 10 Apr 2025DKK 114.7bDKK 27.3bDKK 7.7b10.3x14.9x4.2x
Sat, 08 Mar 2025DKK 156.9bDKK 27.3bDKK 7.7b13.3x20.4x5.7x
Mon, 03 Feb 2025DKK 158.5bDKK 26.0bDKK 4.7b16.5x33.8x6.1x
Wed, 01 Jan 2025DKK 160.9bDKK 26.0bDKK 4.7b16.7x34.3x6.2x
Fri, 29 Nov 2024DKK 163.4bDKK 26.0bDKK 4.7b17x34.8x6.3x
Sun, 27 Oct 2024DKK 179.0bDKK 25.5bDKK 5.5b21.3x32.7x7x
Tue, 24 Sep 2024DKK 191.9bDKK 25.5bDKK 5.5b23.3x35.1x7.5x
Thu, 22 Aug 2024DKK 199.2bDKK 26.1bDKK 5.7b20.3x34.7x7.6x
Sat, 20 Jul 2024DKK 195.0bDKK 24.8bDKK 5.6b18.2x34.6x7.9x
Mon, 17 Jun 2024DKK 172.3bDKK 24.8bDKK 5.6b17.2x30.6x6.9x
Wed, 15 May 2024DKK 184.1bDKK 25.2bDKK 6.2b16.4x29.9x7.3x
Fri, 12 Apr 2024DKK 183.8bDKK 23.9bDKK 5.0b19.4x36.5x7.7x
Sun, 10 Mar 2024DKK 193.7bDKK 23.9bDKK 5.0b19.9x38.5x8.1x
Tue, 06 Feb 2024DKK 167.8bDKK 23.3bDKK 4.2b22.8x40.3x7.2x
Thu, 04 Jan 2024DKK 174.6bDKK 23.3bDKK 4.2b25.7x41.9x7.5x
Sat, 02 Dec 2023DKK 173.8bDKK 23.3bDKK 4.2b25.2x41.8x7.5x
Mon, 30 Oct 2023DKK 158.4bDKK 22.0bDKK 4.7b18.5x33.4x7.2x
Wed, 27 Sep 2023DKK 198.1bDKK 22.0bDKK 4.7b23.2x41.8x9x
Fri, 25 Aug 2023DKK 197.9bDKK 22.0bDKK 4.7b23.7x41.9x9x
Sun, 23 Jul 2023DKK 211.1bDKK 19.5bDKK 4.4b41.8x47.9x10.8x
Tue, 20 Jun 2023DKK 204.3bDKK 19.5bDKK 4.4b42.5x46.4x10.5x
Thu, 18 May 2023DKK 216.2bDKK 17.9bDKK 4.0b33.3x54.1x12.1x
Sat, 15 Apr 2023DKK 212.7bDKK 17.9bDKK 3.5b33.3x60.1x11.9x
Mon, 13 Mar 2023DKK 189.1bDKK 17.9bDKK 3.5b29.2x53.3x10.6x
Wed, 08 Feb 2023DKK 204.2bDKK 14.7bDKK 3.3b31.2x62.4x13.9x
Fri, 06 Jan 2023DKK 220.9bDKK 14.7bDKK 3.3b34.4x67.5x15x
Price to Earnings Ratio

67.5x


Total Market Cap: DKK 220.9bTotal Earnings: DKK 3.3bTotal Revenue: DKK 14.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 33.9x20242025
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 9.5x which is lower than its 3-year average PE of 34.0x.
  • The 3-year average PS ratio of 7.5x is higher than the industry's current PS ratio of 4.4x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 80% per year over the last three years.
  • Revenues for these companies have grown 40% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market3.56%
Healthcare5.92%
Biotech0.46%
Biotech0.46%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ZEAL Zealand PharmaDKK 483.701.7%
+DKK 583.4m		-32.4%PE5.2x
GMAB GenmabDKK 2.08k0.1%
+DKK 184.8m		39.4%PE12.7x
BAVA Bavarian NordicDKK 191.150.3%
+DKK 39.1m		1.0%PE6.1x
BIOPOR BioPortoDKK 1.040.4%
+DKK 2.0m		-32.9%PS14.1x
STRAP Strategic PartnersDKK 686.005.5%
+DKK 1.5m		-16.9%PB1.6x

Latest News

ZEAL
DKK 483.70
Zealand Pharma
7D
1.7%
1Y
-32.4%

ZEAL: Next Generation Metabolic Partnership Will Drive Future Upside Potential

Analysts have nudged their price target for Zealand Pharma slightly higher to approximately $774 per share from about $773, citing modestly lower discount rate assumptions. These more than offset slightly weaker long term revenue growth and profit margin expectations.
BAVA
DKK 191.15
Bavarian Nordic
7D
0.3%
1Y
1.0%
GMAB
DKK 2,080.00
Genmab
7D
0.1%
1Y
39.4%

GMAB Merus Deal Will Likely Expose Downside Risk At Current Levels

Analysts have lifted Genmab's fair value estimate from DKK 1,015 to about DKK 1,076, reflecting a series of higher price targets that cite the Merus acquisition's boost to the late stage pipeline and underappreciated royalty revenue upside as key drivers. Analyst Commentary Recent Street research on Genmab remains broadly constructive, with multiple firms lifting price targets and highlighting the strategic merits of the Merus acquisition.
BIOPOR
DKK 1.04
BioPorto
7D
0.4%
1Y
-32.9%
STRAP
DKK 686.00
Strategic Partners
7D
5.5%
1Y
-16.9%